By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Xanthus Pharmaceuticals, Inc. 

2020 University Street
Suite 2000
Montreal  Quebec  H3A 2A5  Canada
Phone: 514-843-5959 Fax: 514-843-9941



Company News
Antisoma PLC (ASM.L) Completes Acquisition of Xanthus Pharmaceuticals, Inc. 6/11/2008 10:50:12 AM
Antisoma PLC (ASM.L)'s Acquisition of Xanthus Pharmaceuticals, Inc. Approved by Shareholders 6/10/2008 9:02:56 AM
Xanthus Pharmaceuticals, Inc. Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML 6/2/2008 8:42:44 AM
Antisoma PLC (ASM.L) To Acquire Xanthus Pharmaceuticals, Inc. For USD $52.2M 5/16/2008 8:45:16 AM
Xanthus Pharmaceuticals, Inc.' Symadex Reverses Disease in Preclinical Mouse Models of Multiple Sclerosis 4/16/2008 8:39:16 AM
Xanthus Pharmaceuticals, Inc. Presents Data Supporting Distinctive Mechanism of Action for Xanafide(R) 4/15/2008 8:30:33 AM
Xanthus Pharmaceuticals, Inc. Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA 1/22/2008 8:34:39 AM
Xanthus Pharmaceuticals, Inc. Receives Orphan Drug Designation for Oral Fludarabine for the Treatment of CLL 1/3/2008 8:57:13 AM
Xanthus Pharmaceuticals, Inc.'s Symadex Demonstrates Ability to Increase Spinal Cord Remyelination in Multiple Sclerosis Model 12/11/2007 11:51:54 AM
Xanthus Pharmaceuticals, Inc. Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia 10/8/2007 8:18:20 AM